Basal Cell Carcinoma: Pathology, Current Clinical Treatment, and Potential Use of Lipid Nanoparticles

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 10

PMID 35681758

Authors

Izabela Lasinska

Aleksandra Zielinska

Jacek Mackiewicz

Eliana B Souto

Affiliations

Soon will be listed here.

Abstract

Skin cancer is the most common type of carcinoma diagnosed worldwide, with significant morbidity and mortality rates among Caucasians, in particular basal cell carcinoma (BCC). The main risk factors of BCC are well-identified, and there are many chemotherapeutic drugs available for its treatment. The effectiveness of therapeutic options is governed by several factors, including the location of the tumor, its size, and the presence of metastases (although rare for BCC). However, available treatments are based on non-targeted approaches, which encounter a significant risk of systemic toxicity in several organs. Site-specific chemotherapy for BCC has been proposed via the loading of anticancer drugs into nanoparticles. Among various types of nanoparticles, in this review, we focus on potential new regimens for the treatment of BCC using classical anticancer drugs loaded into novel lipid nanoparticles. To meet patient aesthetic expectations and enhance the effectiveness of basal cell carcinoma treatment, new therapeutic topical strategies are discussed, despite a limited number of reports available in the literature.

Citing Articles

Knowledge map and emerging trends of oxidative stress in wound healing: A bibliometric analysis from 2000 to 2023.

Bu F, Yu K, Wang J, Rong L, Li Q Medicine (Baltimore). 2025; 104(10):e39970.

PMID: 40068035 PMC: 11902982. DOI: 10.1097/MD.0000000000039970.

Advancements in skin cancer treatment: focus on photodynamic therapy: a review.

Xu M, Kong L, Jamil M Am J Cancer Res. 2024; 14(10):5011-5044.

PMID: 39553219 PMC: 11560809. DOI: 10.62347/JOUT3260.

Basal Cell Carcinoma: Comprehensive Review with Emphasis on Scar Tissue Manifestation and Post-Vaccination Incidence.

Knecht-Gurwin K, Stefaniak A, Chlebicka I, Szepietowski J Biomedicines. 2024; 12(8).

PMID: 39200233 PMC: 11351840. DOI: 10.3390/biomedicines12081769.

Antitumor Profile of Combined Flower Extract and 5-Fluorouracil Chemotherapy in Sarcoma 180 In Vivo Model.

Santos S, Amaral R, Graca A, Gomes S, Santana F, de Oliveira I Toxics. 2023; 11(4).

PMID: 37112602 PMC: 10141557. DOI: 10.3390/toxics11040375.

References

Craciun A, Barhalescu M, Agop M, Ochiuz L . Theoretical Modeling of Long-Time Drug Release from Nitrosalicyl-Imine-Chitosan Hydrogels through Multifractal Logistic Type Laws. Comput Math Methods Med. 2019; 2019:4091464. PMC: 6710764. DOI: 10.1155/2019/4091464. View

Dummer R, Guminksi A, Gutzmer R, Lear J, Lewis K, Chang A . Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2019; 182(6):1369-1378. PMC: 7318253. DOI: 10.1111/bjd.18552. View

Kim D, Kus K, Ruiz E . Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2018; 33(1):13-24. DOI: 10.1016/j.hoc.2018.09.004. View

Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X . Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019; 48(11):2967-3014. DOI: 10.1039/c8cs00805a. View

Pinton P, Licitra L, Peris K, Santoro A, Ascierto P . Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. Future Oncol. 2015; 11(9):1429-35. DOI: 10.2217/fon.15.20. View

Stratigos A, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M . Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021; 22(6):848-857. DOI: 10.1016/S1470-2045(21)00126-1. View

Andreani T, Fangueiro J, Jose S, Santini A, Silva A, Souto E . Hydrophilic Polymers for Modified-Release Nanoparticles: A Review of Mathematical Modelling for Pharmacokinetic Analysis. Curr Pharm Des. 2015; 21(22):3090-6. DOI: 10.2174/1381612821666150531163617. View

Crow L, Jambusaria-Pahlajani A, Chung C, Baran D, Lowenstein S, Abdelmalek M . Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. Transpl Int. 2019; 32(12):1268-1276. DOI: 10.1111/tri.13520. View

Schmitz L, Novak B, Hoeh A, Luebbert H, Dirschka T . Epidermal penetration and protoporphyrin IX formation of two different 5-aminolevulinic acid formulations in ex vivo human skin. Photodiagnosis Photodyn Ther. 2015; 14:40-6. DOI: 10.1016/j.pdpdt.2015.11.004. View

10.

Tse B, Ireland R, Lee J, Marsh-Wakefield F, Kok L, Don A . Exposure to Systemic Immunosuppressive Ultraviolet Radiation Alters T Cell Recirculation through Sphingosine-1-Phosphate. J Immunol. 2021; 207(9):2278-2287. DOI: 10.4049/jimmunol.2001261. View

11.

Calienni M, Febres-Molina C, Llovera R, Zevallos-Delgado C, Tuttolomondo M, Paolino D . Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment. Int J Pharm. 2019; 565:108-122. DOI: 10.1016/j.ijpharm.2019.05.002. View

12.

Mohammadpour R, Dobrovolskaia M, Cheney D, Greish K, Ghandehari H . Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev. 2019; 144:112-132. PMC: 6745262. DOI: 10.1016/j.addr.2019.07.006. View

13.

Souto E, Souto S, Zielinska A, Durazzo A, Lucarini M, Santini A . Perillaldehyde 1,2-epoxide Loaded SLN-Tailored mAb: Production, Physicochemical Characterization and In Vitro Cytotoxicity Profile in MCF-7 Cell Lines. Pharmaceutics. 2020; 12(2). PMC: 7076521. DOI: 10.3390/pharmaceutics12020161. View

14.

Sutunkova M, Katsnelson B, Privalova L, Gurvich V, Konysheva L, Shur V . On the contribution of the phagocytosis and the solubilization to the iron oxide nanoparticles retention in and elimination from lungs under long-term inhalation exposure. Toxicology. 2016; 363-364:19-28. DOI: 10.1016/j.tox.2016.07.006. View

15.

Verkouteren B, Cosgun B, Reinders M, Kessler P, Vermeulen R, Klaassens M . A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol. 2021; 186(2):215-226. PMC: 9298899. DOI: 10.1111/bjd.20700. View

16.

Singh R, Dhanyamraju P, Lauth M . DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway. Oncotarget. 2016; 8(1):833-845. PMC: 5352201. DOI: 10.18632/oncotarget.13662. View

17.

Ciazynska M, Kaminska-Winciorek G, Lange D, Lewandowski B, Reich A, Slawinska M . The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021; 11(1):4337. PMC: 7900109. DOI: 10.1038/s41598-021-83502-8. View

18.

Swaney M, Kalan L . Living in Your Skin: Microbes, Molecules, and Mechanisms. Infect Immun. 2021; 89(4). PMC: 8090955. DOI: 10.1128/IAI.00695-20. View

19.

Piaserico S, Piccioni A, Gutierrez Garcia-Rodrigo C, Sacco G, Pellegrini C, Fargnoli M . Sequential treatment with calcitriol and methyl aminolevulinate-daylight photodynamic therapy for patients with multiple actinic keratoses of the upper extremities. Photodiagnosis Photodyn Ther. 2021; 34:102325. DOI: 10.1016/j.pdpdt.2021.102325. View

20.

Seidl-Philipp M, Frischhut N, Hollweger N, Schmuth M, Nguyen V . Known and new facts on basal cell carcinoma. J Dtsch Dermatol Ges. 2021; 19(7):1021-1041. PMC: 8361778. DOI: 10.1111/ddg.14580. View